Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0640

+6.7%

Nov 28 10:34 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: NTTG	6/4/2012 11:03:45 AM
	2 Recommendations of 13111

Interesting reports from ASCO: Dabrafenib offers better PFS that dicarbazine (DTIC-Dome therapy) for 250 patients studies with stage III disease and V600E mutations in MM Trametinib offers improved PFS and survival vs chemotherapy (presented at ASCO and published simultaneously in the NEJM) An interesting PII report on combined HyperAcute immunotherapy + peg interferon in MM More insight on cabozantinib for HCC; benefit is similar for patients with and without prior Tx with Sorafenib Not bad for morning reading over coffee

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next